Published in Cancer Res on April 20, 2010
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. PLoS One (2012) 0.99
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97
Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS One (2012) 0.95
CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One (2013) 0.93
Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci (2013) 0.88
SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res (2014) 0.87
Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease. Exp Mol Med (2010) 0.86
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines (2014) 0.85
Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model. Toxins (Basel) (2012) 0.82
Recombinant Salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL. J Biomed Sci (2013) 0.80
4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression. PLoS One (2016) 0.78
Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice. Oncotarget (2016) 0.76
SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer. Oncoimmunology (2015) 0.75
Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines. Oncoimmunology (2013) 0.75
Soluble expression of recombinant human CD137 ligand in Escherichia coli by co-expression of chaperones. J Ind Microbiol Biotechnol (2011) 0.75
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol (2005) 9.91
Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 8.42
CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 7.46
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
Avidin and streptavidin. Methods Enzymol (1990) 5.47
In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 5.07
Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 4.12
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol (2004) 3.59
Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol (2006) 3.57
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol (2001) 3.39
Cancer vaccines: between the idea and the reality. Nat Rev Immunol (2003) 3.24
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 3.14
Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol (2001) 3.05
Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest (2002) 2.55
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol (2007) 1.93
Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J Immunol (2007) 1.82
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol (2002) 1.65
Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol (2006) 1.62
Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol (2007) 1.58
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med (1998) 1.54
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res (2008) 1.51
Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol (2007) 1.48
Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer (1998) 1.38
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes (2005) 1.29
Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res (2009) 1.26
B cells directly tolerize CD8(+) T cells. J Exp Med (1998) 1.20
Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J Immunol (2007) 1.15
The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol (2008) 1.09
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine (2009) 1.09
4-1BB functions as a survival factor in dendritic cells. J Immunol (2009) 1.05
CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol (2008) 1.05
Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem (2005) 1.01
Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol (2005) 0.99
Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells. Transplantation (2005) 0.87
Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro. Cell Mol Immunol (2004) 0.81
ProtEx technology for the generation of novel therapeutic cancer vaccines. Exp Mol Pathol (2009) 0.79
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol (2012) 7.32
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Novel, acentric metal-organic coordination polymers from hydrothermal reactions involving in situ ligand synthesis. Angew Chem Int Ed Engl (2002) 7.04
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
Merkel cell carcinoma and HIV infection. Lancet (2002) 4.72
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol (2012) 4.17
Concerted action of poly(A) nucleases and decapping enzyme in mammalian mRNA turnover. Nat Struct Mol Biol (2005) 4.01
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Synthesis of novel chiral and acentric coordination polymers by the reaction of zinc or cadmium salts with racemic 3-pyridyl-3-aminopropionic acid. Chemistry (2004) 3.49
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 3.41
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Highly stable olefin-Cu(I) coordination oligomers and polymers. Chem Soc Rev (2005) 2.72
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol (2011) 2.38
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
The draft genome of watermelon (Citrullus lanatus) and resequencing of 20 diverse accessions. Nat Genet (2012) 2.33
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat Immunol (2012) 2.17
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov (2011) 2.14
Large anisotropy and effect of deuteration on permittivity in an olefin copper(I) complex. Angew Chem Int Ed Engl (2007) 2.12
Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology (2012) 2.11
Do mitochondria contribute to left ventricular non-compaction cardiomyopathy? New findings from myocardium of patients with left ventricular non-compaction cardiomyopathy. Mol Genet Metab (2013) 2.08
How to make the best use of intraoperative motor evoked potential monitoring? Experience in 1162 consecutive spinal deformity surgical procedures. Spine (Phila Pa 1976) (2014) 2.02
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med (2007) 1.94
A novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal defect. J Hum Genet (2010) 1.89
Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol (2007) 1.85
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog (2002) 1.83
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest (2004) 1.82
Elevated blood pressure linked to primary hyperaldosteronism and impaired vasodilation in BK channel-deficient mice. Circulation (2005) 1.80
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res (2008) 1.77
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
1-[(3-Methyl-piperidin-1-yl)(phen-yl)meth-yl]-2-naphthol. Acta Crystallogr Sect E Struct Rep Online (2009) 1.72
System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner. Magn Reson Med (2004) 1.71
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle (2011) 1.67
A permissive role of mushroom body α/β core neurons in long-term memory consolidation in Drosophila. Curr Biol (2012) 1.67
Can deliberately incomplete gene sample augmentation improve a phylogeny estimate for the advanced moths and butterflies (Hexapoda: Lepidoptera)? Syst Biol (2011) 1.65
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64
Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase. Chem Biol (2010) 1.60
The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat Rev Immunol (2010) 1.60
Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A (2007) 1.59
Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res (2008) 1.58
Cytometric detection of chromatin relaxation, an early reporter of DNA damage response. Cell Cycle (2009) 1.55
Major trends in human parasitic diseases in China. Trends Parasitol (2010) 1.54
Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology (2010) 1.51
Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity (2012) 1.50
Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol (2007) 1.48
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol (2007) 1.48
Homochiral Zn and Cd coordination polymers containing amino acid-tetrazole ligands. Inorg Chem (2003) 1.46
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology (2006) 1.44
MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys (2004) 1.44
Different rates of DNA replication at early versus late S-phase sections: multiscale modeling of stochastic events related to DNA content/EdU (5-ethynyl-2'deoxyuridine) incorporation distributions. Cytometry A (2014) 1.42
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A (2008) 1.42
3,3'-{1,1'-Methyl-enebis[naphthalene-2,1-diylbis(oxymethyl-ene)]}dibenzonitrile. Acta Crystallogr Sect E Struct Rep Online (2008) 1.42
Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol (2006) 1.42
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol (2011) 1.41
The mechanisms of human hotdog-fold thioesterase 2 (hTHEM2) substrate recognition and catalysis illuminated by a structure and function based analysis. Biochemistry (2009) 1.40
Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis (2013) 1.40
Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology (2008) 1.38
Longitudinal tracking of recipient macrophages in a rat chronic cardiac allograft rejection model with noninvasive magnetic resonance imaging using micrometer-sized paramagnetic iron oxide particles. Circulation (2008) 1.38
Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem (2002) 1.38
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol (2009) 1.37
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res (2008) 1.35
Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol (2007) 1.35
PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Res (2003) 1.35
5-Methyl-1-phenyl-1H-1,2,3-triazole-4-carboxylic acid. Acta Crystallogr Sect E Struct Rep Online (2008) 1.34
Neuroprotective effect of Alpinia oxyphylla Miq. fruits against glutamate-induced apoptosis in cortical neurons. Toxicol Lett (2003) 1.34
Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol (2007) 1.32
A high resolution genetic map anchoring scaffolds of the sequenced watermelon genome. PLoS One (2012) 1.32
Analysis of apoptosis by cytometry using TUNEL assay. Methods (2008) 1.32
TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol (2011) 1.29
Divergence of function in the hot dog fold enzyme superfamily: the bacterial thioesterase YciA. Biochemistry (2008) 1.28
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. J Bone Miner Res (2012) 1.27
5-Methyl-1-(3-nitro-benz-yl)-1H-1,2,3-triazole-4-carboxylic acid monohydrate. Acta Crystallogr Sect E Struct Rep Online (2008) 1.27
The knowledge-integrated network biomarkers discovery for major adverse cardiac events. J Proteome Res (2008) 1.27